Current high-throughput technologies enable simultaneous acquisition of multi-level omics data such as genome, transcriptome, proteome and phosphatome data. Interpretation of these data as a whole is a confronting challenge of the biological field. The efficient, combined approach can lead to system-level analyses for the prediction and characterization of selective drug response on target diseases. Discovery studies on clinically relevant drug applications and their mode of actions are accelerated by integrating multi-level omics data with chemical or siRNA screening data on diverse biological samples. For this purpose, we have addressed this challenge by constructing a smart screening platform that combines technologies on computer-oriented big data mining and experimental high content screening for last several years.
展开▼
